ARM•November 16, 2026 at 2:33 PM UTCSemiconductors & Semiconductor Equipment

Arm's 27.7% Monthly Plunge Tests the Silicon Bet and Litigation Overhang

Read source article

What happened

Arm shares slid 27.7% in a month despite a revenue beat, as investors rotated away from high-multiple AI names and focused on unresolved execution risks. The AGI CPU remains the swing factor: management has line of sight to over $2 billion of demand but only guided to $1 billion due to supply constraints, and no material revenue has been recognized yet. A looming Qualcomm litigation date adds another layer of uncertainty over licensing rights and royalty streams. With the stock now trading near our bear-case value of $210, the valuation is less extreme, but the market is clearly demanding proof of commercialization rather than promise. The three catalysts—AGI CPU shipments, sustained 20%+ royalty growth, and legal clarity—could re-rate the stock, but none are yet confirmed.

Implication

Arm's recent price action confirms that the market is no longer willing to pay for optionality on the AGI CPU or unproven hyperscaler royalty acceleration. While the revenue beat shows underlying demand is intact, the supply-chain bottlenecks and legal overhang create binary outcomes that are difficult to underwrite at current levels. For existing holders, the risk-reward has improved but remains skewed negative if AGI CPU revenue slips beyond FQ4 FY2027 or if Qualcomm gains further legal traction. For new investors, we would prefer to see either a decisive break above $220 with confirming fundamental news or a further pullback to the $180-200 range that prices in a more pessimistic scenario. Until one of the three catalysts materializes—first AGI CPU revenue, a raised outlook above $1 billion, or a favorable litigation ruling—we recommend staying on the sidelines.

Thesis delta

The thesis shifts from a pure wait-and-see to a more balanced risk-reward after the 27.7% price correction. The stock now trades near our bear-case implied value of $210, reducing downside but still lacks a positive catalyst to justify a higher rating. We maintain WAIT but acknowledge that entry near $200 would offer a more attractive margin of safety if AGI CPU execution remains on track.

Confidence

Medium